The FDA has granted accelerated approval to talquetamab-tgvs (Talvey™, Janssen Biotech, Inc.) for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least 4 prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody.   Why it matters: "G protein–coupled receptor, family C, group 5, member D (GPRC5D) is an orphan receptor expressed in malignant plasma cells," wrote Ajai Chari, Direct...

Oncology Data Advisor™ · Exploring the Results of Elranatamab for Relapsed/Refractory Multiple Myeloma With Noopur Raje, MD Recently, Dr. Noopur Raje, Director of the Center for Multiple Myeloma at Massachusetts General Hospital, sat down with Oncology Data Advisor at the 64th American Society of Hematology (ASH) Annual Meeting to discuss the results of the MagnetisMM-1 study of elranatamab for multiple myeloma that she presented. Dr. Raje elaborates on the efficacy and safety of th...

i3 Health has provided a nursing continuing professional development (NCPD)–approved activity, Multiple Myeloma: Enhancing Treatment Tolerability, Adherence, and Patient-Centered Care, during which the health care team was challenged to address knowledge gaps experienced in this field. Multiple myeloma (MM) is a B-cell neoplasm characterized by aberrant expansion of plasma cells within the bone marrow and extramedullary sites. The American Cancer Society approximates 35,730 new cases of MM to be...

The FDA has approved pacritinib (VonjoTM, CTI BioPharma) for the treatment of adult patients with intermediate- to high-risk primary or secondary myelofibrosis with a platelet count below 50x109/L. Pacritinib is a novel oral kinase inhibitor which inhibits Janus kinase 2 (JAK2) with minimal myelosuppression. Previous treatments available for intermediate- and high-risk myelofibrosis have not been approved for patients with severe cytopenia. "Pacritinib can provide a treatment option for patients...